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Effectiveness and adverse effects of deep brain stimulation: umbrella review of 
meta-analyses 
Abstract 
Background This umbrella review summarizes the evidence across meta-analyses regarding the 
effectiveness and adverse effects of deep brain stimulation (DBS). 
Methods Databases were searched up to March 2015 for meta-analyses of comparative trials in 
humans assessing the effectiveness or adverse effects of DBS. Data selection, data extraction, 
and risk of bias assessment was performed by two independent reviewers. 
Results Seven eligible systematic reviews were included assessing the use of DBS for epilepsy (n 
= 1), obsessive-compulsive disorder (n = 1) and Parkinson’s disease (n = 5). The summary 
estimates were significant at p ≤ 0.05 in 4 meta-analyses (27%) with both fixed- and random-
effects. One meta-analysis reported that DBS was more effective than sham in reducing the 
Yale–Brown Obsessive Compulsive Scale score in obsessive compulsive disorder patients. The 
remaining three meta-analyses reported differences regarding mortality and depression in 
patients with Parkinson’s disease between DBS of the subthalamic nucleus and of the globus 
pallidus internus. Of the 15 meta-analyses, none compiled adequately robust evidence. 
Conclusions Though DBS has emerged as a viable surgical intervention to treat various disabling 
neurological symptoms, existing studies fail to adequately support its use based on robust 
evidence without hints of bias. 
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Manuscript Text 
Introduction 
Rationale 
Deep brain stimulation (DBS) has emerged as a novel neurosurgical method to treat 
movement disorders, such as Parkinson’s disease,1 essential tremor,2-4 chronic pain,5 
Tourette’s syndrome,6 and psychiatric disorders, like obsessive compulsive disorder,7 
depression,8-10 and anorexia nervosa.11 High-frequency stimulating electrodes are placed in 
one of several target areas in the brain, including the ventrolateral thalamus, subthalamic 
nucleus (STN) or internal segment of the globus pallidus (GPi) and periaqueductal grey 
matter, and is connected to an implantable pulse generator. DBS involves the delivery of 
precise electrical signals to specific deep anatomical structures in the central nervous 
system. DBS is thought to affect the firing rates and bursting patterns of neurons and, 
ultimately, the synchronized oscillatory activity of neuronal networks.12-13 
 
Objectives 
For some of the abovementioned neurological conditions, several randomized controlled 
trials and systematic reviews thereof have been published in the last decade, but have not 
been systematically evaluated up to now. To evaluate the strength of evidence regarding 
the clinical indication for the use of DBS, we performed an umbrella review of the evidence 
across meta-analyses pertaining to the effectiveness or adverse effects of DBS. We aimed to 
assess the direction and magnitude of existing effects, as well as evaluate whether there are 
hints of biases in the literature that could endanger the validity of the results. 
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Materials and Methods 
Literature search 
Two researchers (PNP and SNP) independently searched MEDLINe through PubMed, 
Scopus, the Cochrane Database of Systematic Reviews, and the Cochrane Database of 
Abstracts of Reviews of Effects from inception to the end of March 2015 for meta-analyses 
or systematic reviews of studies investigating the effectiveness or adverse effects of deep 
brain stimulation. The exact literature search for each database can be seen in Appendix A. 
The references from eligible systematic or narrative reviews were also checked. The titles, 
abstracts, and full-texts of the resulting papers were examined in detail, and discrepancies 
were resolved by a third researcher (JD). 
 
Eligibility criteria and data extraction 
Articles were eligible, if the authors had performed a systematic search to identify 
pertinent clinical trials on DBS in humans and had performed quantitative data synthesis 
comparing at least two experimental/control groups. We included systematic reviews on 
both randomised controlled trials (RCT) and non-RCTs. Meta-analyses or systematic 
reviews that did not present study specific data were excluded, but the data were 
requested from corresponding author. We included meta-analyses of both binary and 
continuous outcomes. If an article presented separate meta-analyses on more than one 
eligible outcome, those were assessed separately. Whenever more than one meta-analysis 
existed on the same scientific question, the meta-analysis with the largest number of 
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studies and/or the most complete reporting was selected, but we conducted sensitivity 
analyses to assess any differences in these duplicate meta-analyses. 
From each eligible systematic review, two authors (PNP and SNP) abstracted 
independently information on publication type, number of searched databases, search 
period, type of included trials, number of assessed outcomes (including measures against 
multiple testing), and citation counts from Google Scholar (http://scholar.google.com). We 
recorded if the included systematic reviews assessed the risk of bias of the individual 
studies and the quality of evidence according to the GRADE approach,14 but we did not 
perform these procedures ourselves, as this task was beyond the scope of this umbrella 
review. Additionally, we appraised the methodological quality of the included systematic 
reviews with the AMSTAR tool.15 Finally, we assessed the risk of bias of the included 
systematic reviews with the newly-designed ROBIS tool.16 
From each eligible meta-analysis, the same two authors abstracted information 
independently on first author, year of publication, outcome examined, number of included 
studies, and reported data at the individual trial level. For each of the included studies in 
each eligible meta-analysis, we recorded the study design (RCT or non-RCT), the number of 
cases (for binary outcomes) and population participants.  
 
Assessment of summary effects and heterogeneity 
For meta-analyses of continuous outcomes, Standardized Mean Differences (SMDs) were 
chosen as effect estimates. Binary outcomes were also transformed to SMDs in order to 
enable synthesis of both continuous and binary outcomes together. 
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We estimated the summary effects using both fixed-effect and inverse variance 
random-effects models.17 Fixed-effect meta-analysis relies on the assumption that a unique 
effect underlies every study in the meta-analysis and no heterogeneity between studies 
exists. A random-effects synthesis makes the assumption that individual studies are 
estimating different effects, which are assumed to have a normal distribution. The random-
effects meta-analysis is performed to estimate the mean of this distribution of effects 
across different studies and the uncertainty about that mean (95% confidence interval 
(CI)). We also calculated the 95% prediction interval (PrI) for the summary random-effects 
estimates, which further account for heterogeneity between studies and indicate the 
uncertainty for the effect that would be expected in a new study examining that same 
association.18 The 95% PrI shows where the true effects are for 95% of the studies from the 
population of studies that are synthesised or similar (exchangeable) studies that might be 
done in the future. 
We assessed heterogeneity between studies using the P value of the χ2 based 
Cochran Q test and the I2 metric of inconsistency; this could reflect either genuine diversity 
or bias. The Q test is obtained by the weighted sum of the squared differences of the 
observed effect in each study minus the fixed summary effect.19 The I2 metric ranges 
between 0% and 100% and is the ratio of variance between studies over the sum of the 
variances within and between studies. The 95 % CIs around I2 were calculated according to 
the non-central chi-square approximation of Q.20 
A sensitivity analysis according to the basic study design of included trials21 was 
conducted with mixed-effects subgroup analysis (random-effects meta-regression) and by 
calculating the ΔSMDs (difference in SMDs) and the associated 95% CIs. An iterative 
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residual maximum likelihood algorithm was used for the estimation of between-study 
variance because of its performance,22 while the Knapp-Hartung modification23 was used 
for the calculation of the ΔSMDs, which accounts for the uncertainty in the heterogeneity 
estimate.24 The effect magnitude both for SMD and ΔSMD was conventionally judged as 
0.2=small effect, 0.5=medium effect, and 0.8= large effect.25 The cut-off of SMD or 
ΔSMD>0.8 was used to construct contours of large effect magnitude in all forest plots. 
 
Assessment of small study effects 
We examined whether there is an indication for small study effects - that is, if small studies 
tend to give higher estimates than large studies. Small study effects can indicate publication 
bias or other reporting biases, but they can also reflect genuine heterogeneity, chance, or 
other reasons for differences between small and large studies.26 We used the regression 
asymmetry test proposed by Egger27 to investigate funnel plot asymmetry. The alternative 
test proposed by Harbord outperforms Egger test, but is applicable only to dichotomous 
outcomes.28 
 
Associations meeting further criteria 
We further identified associations for which the summary fixed and random-effects 
estimates showed strong evidence of significance (P<0.001; a threshold that has been 
suggested to substantially reduce the number of false positive findings29) were based on 
evidence from more than 500 cases for binary outcomes or from more than 5000 
participants for continuous outcomes;30 did not have large heterogeneity between studies 
(I2<75%); their 95% PrI excluded the null value; and had no evidence of small study effects 
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(from Egger test). All calculations were performed in STATA version 12. All P values are 
two-sided, while statistical significance is set at 5% for all tests, except for heterogeneity 
and Egger tests (10%). Although multiple P values are reported in this umbrella review, no 
correction or adjustment was performed, as we aimed to summarize the results of the 
included papers. 
 
Results 
Characteristics of included systematic reviews 
A total of 100 hits were received from the electronic literature search, while another 3 
papers were added manually (Fig. 1). After removal of duplicates, screening and 
application of the inclusion criteria, a total of 7 systematic reviews were included in this 
umbrella review31-37 (Table 1; Appendix B). A total of 18 reviews with potentially eligible 
meta-analyses were excluded from the umbrella review, as they did not include 
conventional pairwise meta-analytic comparisons, but performed averaging among studies, 
pooled single group estimates, or generated control group data from expert opinions. 
Missing data at the trial level were requested in two instances (Appendix B), but no answer 
was received and the reviews were excluded. Chambers and Bowen32 performed meta-
analysis of both DBS and vagus nerve stimulation at various stimulation degrees for the 
treatment of epilepsy, but only the subgroup on DBS (one single trial) is included in this 
umbrella review. 
Four reviews were published in scientific journals32-34,36 one was published in the 
Cochrane Library,37 while the rest two were posters from a scientific congress (Appendix 
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B).31,35 All reviews were in English, published after 2013 and searched 1-4 literature 
databases. Five reviews32-34,36-37 included only RCTs, while remaining two31,35 included 
both RCTs and non-RCTs. Four reviews31,34,36,37 reported more than one primary outcomes 
in their analyses, but no measure was taken to safeguard against increased Type I errors. 
 
Risk of bias and methodological adequacy 
Out of the seven included systematic reviews, 4 of them32-34,37 (57%) assessed the risk of 
bias in the included trials; all of them with the Cochrane Collaboration’s risk of bias tool. 
Most often sources of bias identified concerned the generation of random sequence,33 
allocation concealment,34 blinding,34,37 incomplete outcome data,37 selective 
reporting,32,33,37 and potentional confounding due to uncontrolled simultaneous drug 
administration.37 
The quality of evidence (strength of recommendations) from the performed meta-
analyses was assessed with the GRADE approach only in 2 out of 7 reviews32,37 (29%). The 
strength of recommendations from the one review comparing on vs off DBS for drug-
resistant epilepsy was low, due to imprecision and hints of publication bias.32 The strength 
of recommendations from the review comparing DBS to sham ranged from very low to 
high, with imprecision, confounding due to missing wash-out period in cross-over trials 
and absence of drug regulation being the reasons to downgrade the quality.37 
The methodological adequacy of the included reviews was appraised with the 
AMSTAR tool. This appraisal was limited only to reviews published in journals or in the 
Cochrane Library, as the two reviews in poster format did not provide adequate 
information. The AMSTAR scores for the five reviews ranged from 2 to 11 (Appendix C-D), 
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with only the Cochrane Review scoring the maximum of 11 points. The main shortcomings 
were lack of a priori design, incomplete reporting of included/excluded studies, and 
missing statements for possible conflicts of interest. 
The risk of bias of the included reviews was appraised with the ROBIS tool. As with 
the appraisal of methodological adequacy, risk of bias was assessed only in reviews 
published in journals or in the Cochrane Library. Four out of five reviews were judged to be 
in high risk of bias (Fig. 2; Table 2; Appendix E), with only the Cochrane Review being in 
low risk of bias. 
 
Summary effect sizes 
A total of 15 unique meta-analyses were extracted from the seven included review: four 
meta-analyses (from one review37) regarding DBS use for drug-resistant epilepsy, one 
meta-analysis (from one review33) regarding DBS use for obsessive compulsive disorder, 
and ten meta-analyses (from 5 reviews31,32,34-36) regarding DBS use for Parkinson’s disease. 
For clarity reasons the results of the included meta-analyses are presented separately 
concerning the efficacy (comparison of active treatment with sham treatment; Table 3; Fig. 
3) and comparative effectiveness (comparison of two active treatments; Table 4; Fig. 4) of 
DBS. 
As far as the efficacy of DBS is concerned the results of the meta-analyses were 
significant at the P≤0.05 level in one instance, both with fixed- and random-effects models: 
absolute effectiveness of DBS compared to sham in patients with obsessive compulsive 
disorder. The results of the largest study, compared to the pooled effect, were almost the 
same in all cases (meta-analyses 3, 8, 10). The 95% PrI did not exclude the null value in any 
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case, indicating that no clinical recommendations can be done on the basis of existing 
evidence. 
As far as the comparative effectiveness of DBS is concerned the results of the meta-
analyses were significant at the P≤0.05 level in three instances, both with fixed- and 
random-effects models, regarding the effectiveness against depressive symptoms or 
minimization of mortality with DBS use for Parkinson’s disease according to the stimulated 
target. The results of the meta-analyses were significant at the P<0.001 level with both 
models regarding the non-motor symptoms of Parkinson’s disease, assessed with the Beck 
Depression Inventory-II. Table 4 also shows the effect of the largest study included in each 
meta-analysis. The results of the largest study, compared to the pooled effect, agreed in 
direction but were more conservative in 4 cases (meta-analyses 1, 2, 3, 5), were almost the 
same in 3 cases (meta-analyses 4, 6, 7) and were on the opposite direction in 3 cases (meta-
analyses 8, 9). The 95% PrI excluded the null value only for the meta-analysis of post-DBS 
depression severity compared to the DBS target (meta-analysis 3). 
 
Overlap among meta-analyses 
Overlaps among meta-analyses existed only regarding the use of DBS in patients with 
Parkinson’s disease. Overlaps existed among three reviews for three studied outcomes, i.e. 
the unified Parkinson's disease rating scale (UPDRS)-II, UPDRS-III off-medication, and 
UPDRS-III on-medication. The review of Liu et al34 was selected over the review of Sako et 
al36 and Arnaout et al,31 based on number of included studies and completeness of the 
analyses, respectively. Both the matrix of included studies and the results of the meta-
analyses with overlap can be seen in the Supplement (Appendix F-G).  
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Heterogeneity and small study effects 
Τhe Q test showed significant heterogeneity (P≤0.10) for two meta-analyses (Table 4), both 
with moderate to high inconsistency (I2 between 50% and 75%). Another meta-analysis 
had moderate inconsistency (52%), while the rest had I2<50%. Uncertainty around the 
heterogeneity estimates was often large, as reflected by wide 95% CIs of the I2. In one of 
the meta-analyses with significant heterogeneity (Table 4; meta-analysis 8) the authors 
conducted a sensitivity analysis by removing the trial with the largest effect, thereby 
reducing the heterogeneity. However, no clinical reasoning was provided for this choice. 
Sensitivity analyses according to the study design of the included trials (RCT or non-RCT) 
were possible in four meta-analyses from two systematic reviews31,35 that included both 
RCTs and non-RCTs (Appendix H). In three out of four meta-analyses, non-RCTs gave hints 
of effect overestimation, which was however non-significant in all cases (P>0.05). However, 
the differences in SMDs ranged between 0.07 and 0.74, the latter approaching the cut-off 
for large effect magnitude (0.8). 
There was no evidence of small study effects, except for one case, where the Egger’s 
test was significant (Table 4; P=0.041). In this meta-analysis the change in semantic verbal 
fluency in Parkinson patients after STN or GPi DBS was more conservative in the larger 
studies. 
 
Associations meeting further criteria 
Of the 15 included meta-analyses, none fulfilled all criteria set (Appendix I) with the 
greatest problem being the limited number of studies/patients included. 
12 
 
 
Discussion 
Principal findings and possible explanations 
We performed an umbrella review to examine the existing evidence from meta-analyses on 
the use of DBS in patients with various disabling neurological symptoms. Although 15 
meta-analyses were finally included, most reported on nominally non-significant effects, 
both pertaining to the effectiveness of DBS and to the minimization of adverse effects. Only 
a small minority of meta-analyses (n=4) reported on statistically significant effects, but 
none of these was based on robust epidemiological evidence. 
 
DBS for obsessive compulsive disorder 
Deep brain stimulation was reported to be more effective in alleviating the disease 
symptoms of patient’s with obsessive compulsive disorder (as measured by the Yale–
Brown Obsessive Compulsive Scale) compared to sham stimulation.33 Although the effects 
were consistent across all five included studies and the random-effects pooled summary 
indicated a large effect magnitude, clear indications of imprecision existed, which resulted 
in uncertainty in the estimates. This can be however remedied by the inclusion of 
additional RCT on this subject that might strengthen the quality of clinical 
recommendations for the use of DBS in obsessive compulsive patients. It has been reported 
that, DBS targeted at the nucleus accumbens of patients with obsessive compulsive 
disorder appears to release dopamine in the striatum, which is associated with increased 
plasma levels of homovanillic acid and improved clinical symptoms. This suggests that DBS 
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may compensate for a defective dopaminergic system. These changes hint at a causal role 
of dopamine in the therapeutic efficacy of DBS, and agree with previous insight into the 
role of dopamine in obsessive compulsive disorder,38,39 but further research is needed to 
confirm this.40 Finally, as suggested by the American Society for Stereotactic and Functional 
Neurosurgery, it is imperative that electrophysiological, morphological (neuroimaging), 
functional, or clinical predictive factors are developed that will enable to identify the most 
apt candidate patients for this procedure.41 
 
DBS for Parkinson’s disease 
One of the most interesting findings of this umbrella review is that no meta-analysis on the 
efficacy of DBS for Parkinson’s disease was identified and included. As far as comparative 
effectiveness is concerned, recent studies have reported that there is no significant 
difference between STN and GPi DBS in improving motor control in patients with 
Parkinson’s disease,42,43 which is the main outcome of interest in Parkinson’s disease. 
However, existing evidence indicates that significant differences exist between STN or GPi 
DBS in patients with Parkinson’s disease, as far as mortality or depression are concerned.34-
36 STN DBS was associated with higher patient mortality than GPi DBS (P<0.01). However, 
the authors of the meta-analysis reported that since most deaths were due to post-
operative complications not directly related to DBS, confounding cannot be excluded.35 
Additionally, it must also be noted, that non-RCTs were also included in this meta-analysis, 
which might have introduced further bias,21 while clear signs of imprecision were also 
present. Furthermore, STN DBS was also associated with greater incidence of depression 
and with more severe depression, as measured with the Beck Depression Inventory II, 
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compared to GPi DBS.34,36 Thus, GPi DBS may be beneficial to treat severe non-motor mood 
symptoms than STN DBS. Some of these non-motor symptoms can even predate the motor 
problems44-46 and are often more disabling and resistant to treatment than motor 
symptoms, being key determinants of quality of life. However, due to the uncertainty 
around the existing results that originate from imprecision, no clear distinction between 
the pros and cons of STN and GPi DBS can be made, and further studies are needed in order 
to form robust clinical recommendations. 
 
Strengths, weaknesses and future research 
Several limitations and caveats should be considered in the interpretation of our findings. 
Firstly, we included only studies used in certain published meta-analyses and thus might 
have missed some individual studies, if those were not identified in the original systematic 
searches. Secondarily, data at the trial level were missing for some meta-analyses and were 
therefore excluded. Thirdly, most of the included systematic reviews presented serious 
methodological inadequacies,47 like inadequate justification for the statistical model48 and 
metric used,49 incomplete assessement of clinical and statistical heterogeneity47 and partial 
risk of bias assessment at the individual trial or meta-analysis level. Finally, funnel plot 
asymmetry was consistently investigated with Egger’s test for all meta-analyses, although 
less than ten trials were included in every case,26 according to previous umbrella 
reviews.30,50,51 
Future research should be directed into planning and conducting blinded RCTs with 
a priori sample size calculations that will enable an adequately-powered assessment of the 
benefits and harms of DBS for its various neurological indications. Furthermore, there is a 
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great number of published RCTs on the use of DBS for various conditions that has not yet 
been systematically appraised, including refractory partial seizures,52 medication-
refractory cervical dystonia,53 essential tremor,54 Alzheimer’s disease,55 and treatment-
resistant depression.56 These could be the focus of future systematic reviews. 
 
Conclusions 
In conclusion, although use of DBS for the treatment of various disabling neurological 
symptoms has been studied to some effect, firm universal conclusions about either its 
efficacy or comparative effectiveness cannot be drawn. There is limited evidence that DBS 
is effective in reducing symptoms in obsessive compulsive disorder patients and that GPi 
DBS is more beneficial than STN DBS in reducing non-motor symptoms in Parkinson’s 
patients. However, these associations do not meet the epidemiological criteria for 
credibility that were set for this umbrella review and further well-designed studies are 
needed. 
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Figure Legends 
Fig. 1 Flowdiagram for the study selection. Number of the systematic reviews identified 
from the electronic search and assessed in this study, together with the number of meta-
analyses extracted from them. 
Fig. 2 ROBIS risk of bias of the included systematic reviews. Assessment of the risk of bias 
regarding the four domains covered by the ROBIS tool: the study eligibility criteria, the 
identification and selection of studies, the data collection and study appraisal, and the 
synthesis of findings. Darker colours indicate overall risk of bias rating; lighter colors 
concern judgments. 
Fig. 3 Forest plot of all included meta-analyses of deep brain stimulation controlled trials 
on efficacy with standardized mean difference as type of metric. Summary of the result of 
all meta-analyses replicated from the included systematic reviews. Abbreviations: SMD, 
standardized mean difference; DBS, deep brain stimulation; YBOCS, Yale–Brown Obsessive 
Compulsive Scale. 
Fig. 4 Forest plot of all included meta-analyses of deep brain stimulation controlled trials 
on comparative effectiveness with standardized mean difference as type of metric. 
Summary of the result of all meta-analyses replicated from the included systematic 
reviews. Abbreviations: SMD, standardized mean difference; DBS, deep brain stimulation; 
STN, subthalamic nucleus; GPi, globus pallidus internus; BDI-II, Beck depression inventory-
II; LED, levodopa equivalent dose; UPDRS, unified Parkinson's disease rating scale. 
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Table Legends 
Table 1 Characteristics of the included systematic reviews. Abbreviations: RCT, 
randomized controlled trial. 
Table 2 Tabular presentation for the ROBIS results of the included systematic reviews. 
Abbreviations: ⊕, low risk; ⊝, high risk; ?, unclear risk. 
Table 3 Results of the included meta-analyses on efficacy (comparison of active 
interventions with sham controls). * p<0.05; ** p<0.01; *** p<0.001; ¥ 
significance results originating from the test for Q. Abbreviations: FE, fixed-effect 
model; RE, random-effects model; N, number of studies; SMD, standardized mean 
difference; CI, confidence interval; PrI, predictive interval; DBS, deep brain 
stimulation; Bin, binary; Effect, effectiveness. 
Table 4 Results of the included meta-analyses on comparative effectiveness (comparison 
of two active interventions). * p<0.05; ** p<0.01; *** p<0.001; †there was overlap 
with the poster report of Arnaout 2015, but the journal report was retained, due 
to completeness. ‡there was overlap with the poster report of Arnaout 2015, and 
the journal report of Sako 2014, but the journal report of Liu 2014, was retained, 
due to completeness and increased number of included studies. ¥ significance 
results originating from the test for Q. Abbreviations: FE, fixed-effect model; RE, 
random-effects model; N, number of studies; SMD, standardized mean difference; 
CI, confidence interval; PrI, predictive interval; DBS, deep brain stimulation; Bin, 
binary; Effect, effectiveness; NA, not applicable; STN, subthalamic nucleus; GPi, 
globus pallidus internus; AE, adverse effects; BDI-II, Beck depression inventory-
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II; LED, levodopa equivalent dose; UPDRS, unified Parkinson's disease rating 
scale. 
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collection and study appraisal, and the synthesis of findings. Darker colours indicate overall risk of bias rating; 
lighter colors concern judgments. 
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included systematic reviews. Abbreviations: SMD, standardized mean difference; DBS, deep brain stimulation; 
YBOCS, Yale–Brown Obsessive Compulsive Scale. 
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Fig. 4 Forest plot of all included meta-analyses of deep brain stimulation controlled trials on comparative 
effectiveness with standardized mean difference as type of metric. Summary of the result of all meta-analyses 
replicated from the included systematic reviews. Abbreviations: SMD, standardized mean difference; DBS, deep 
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levodopa equivalent dose; UPDRS, unified Parkinson's disease rating scale. 
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Effectiveness and adverse effects of deep brain stimulation: umbrella review of meta-analyses 
Tables 
Table 1 Characteristics of the included systematic reviews 
No Review Type 
No of 
databases 
Search period 
Included 
trials 
Outcomes 
Mutliplicity 
addressed 
Citations 
1 Chambers 2013 Journal paper 4 Jan 2007-Dec 2012 RCT 1 - 10 
2 Kisely 2014 Journal paper 2 -Apr 2013 RCT 1 - 7 
3 Liu 2014 Journal paper 4 -Apr 2013 RCT 5 No 0 
4 Sako 2014 Journal paper 1 1995-2013 RCT 7 No 8 
5 Sprengers 2014 Cochrane Review 3 -Aug 2013 RCT 18 No 10 
6 Arnaout 2015 Conference poster 1 -Nov 2014 non-RCT / RCT 5 No - 
7 Negida 2015 Conference poster 1 -Nov 2014 non-RCT / RCT 1 - - 
Abbreviations: RCT, randomized controlled trial. 
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Effectiveness and adverse effects of deep brain stimulation: umbrella review of meta-analyses 
Table 2 Tabular presentation for the ROBIS results of the included systematic reviews 
 
Review Phase 2 Phase 3 
1. study 
eligibility 
criteria 
2. identification 
and selection of 
studies 
3. data collection 
and study 
appraisal 
4. synthesis 
and findings 
risk of bias in 
the review 
Chambers 2013 ⊝ ⊝ ⊝ ⊝ ⊝ 
Kisely 2014 ⊝ ⊝ ⊕ ⊝ ⊝ 
Liu 2014 ⊝ ⊝ ⊝ ⊝ ⊝ 
Sako 2014 ⊝ ⊝ ⊝ ⊝ ⊝ 
Sprengers 2014 ⊕ ⊕ ⊕ ⊕ ⊕ 
Arnaout 2015 ? ? ? ? ? 
Negida 2015 ? ? ? ? ? 
Abbreviations: ⊕, low risk; ⊝, high risk; ?, unclear risk. 
  
Effectiveness and adverse effects of deep brain stimulation: umbrella review of meta-analyses 
Table 3 Results of the included meta-analyses on efficacy (comparison of active interventions with sham controls) 
 
        
FE RE  Largest  Egger 
No First author / Year Experimental Control Scope Nature Outcome N 
Cases/Sam
ple 
SMD (95%CI) SMD (95%CI) 95% PrI SMD (95%CI) I2 (95% CI)¥ P 
 Epilepsy 
       
      
1 Sprengers 2014 Cerebellar DBS Sham Effect. Bin Seizure freedom 3 NR/33 
-0.02 
(-0.83,0.78) 
-0.02 
(-0.83,0.78) 
-5.23,5.18 
0.00 
(-1.16,1.16) 
0% 
(0%,73%) 
- 
2 Sprengers 2014 
Hippocampal 
DBS 
Sham Effect. Bin Seizure freedom 3 NR/21 
0.02 
(-0.87,0.90) 
0.02 
(-0.87,0.90) 
-5.73,5.77 
0.00 
(-1.30,1.30) 
0% 
(0%,73%) 
- 
3 Sprengers 2014 Cerebellar DBS Sham Effect. Bin Responder rate 3 NR/33 
0.49 
(-0.43,1.41) 
0.49 
(-0.43,1.41) 
-5.46,6.44 
0.44 
(-0.78,1.66) 
0% 
(0%,73%) 
- 
4 Sprengers 2014 
Hippocampal 
DBS 
Sham Effect. Bin Responder rate 3 NR/21 
0.10 
(-0.56,0.77) 
0.10 
(-0.56,0.77) 
-4.19,4.40 
0.00 
(-0.81,0.81) 
0% 
(0%,73%) 
- 
 OCD 
       
      
5 Kisely 2014 DBS Sham Effect. Con YBOCS 5 -/52 
-0.87 
(-1.47,-0.27)** 
-0.95 
(-1.74,-0.15)* 
-3.12,1.23 
-0.35 
(-1.42,0.72) 
37% 
(0%,76%) 
- 
 Parkinson’s disease 
       
      
 6 Chambers 2013 Stimulation on 
Stimulatio
n off 
Effect. Bin 
> 50% 
Reduction in 
seizure 
frequency 
1 115/499 
0.10 (-
0.36,0.57) 
- - - - - 
* p<0.05 
** p<0.01 
*** p<0.001 
¥ significance results originating from the test for Q. 
Abbreviations: FE, fixed-effect model; RE, random-effects model; N, number of studies; SMD, standardized mean difference; CI, confidence interval; PrI, predictive interval; DBS, deep brain stimulation; 
Bin, binary; Effect, effectiveness; NR, not reported; OCD, obsessive compulsive disorder; YBOCS, Yale–Brown Obsessive Compulsive Scale. 
  
Effectiveness and adverse effects of deep brain stimulation: umbrella review of meta-analyses 
Table 4 Results of the included meta-analyses on comparative effectiveness (comparison of two active interventions) 
 
        
FE RE  Largest  Egger 
No First author / Year Experimental Control Scope Nature Outcome N 
Cases/Sam
ple 
SMD (95%CI) SMD (95%CI) 95% PrI SMD (95%CI) I2 (95% CI)¥ P 
 Parkinson’s disease 
       
      
1 Sako 2014 DBS (STN) DBS (GPi) AE Bin Depression 3 131/479 
0.41 
(0.17,0.65)** 
0.61 
(0.03,1.19)* 
-5.94,7.16 
0.27 
(0.00,0.54) 
68% 
(0%,89%)* 
- 
2 Negida 2015 DBS (STN) DBS (GPi) AE Bin Mortality 4 44/479 
0.72 
(0.27, 1.18,)** 
0.72 
(0.27,1.18)** 
-0.27,1.72 
0.48 
(-0.12,1.07) 
0% 
(0%,68%) 
- 
3 Liu 2014 DBS (STN) DBS (GPi) Effect. Con BDI-II 5 -/540 
0.39 
(0.22,0.56)*** 
0.39 
(0.22,0.56)*** 
0.12,0.67 
0.30 
(0.07,0.52)* 
0% 
(0%,64%) 
- 
4 Liu 2014 DBS (STN) DBS (GPi) Effect. Con LED 2 -/322 
-0.16 
(-0.38,0.06) 
-0.16 
(-0.38,0.06) 
NA 
-0.18 
(-0.40,0.05) 
0% 
(NA) 
- 
5 Arnaout 2015 DBS (STN) DBS (GPi) Effect. Con 
Phonemic 
verbal fluency 
3 -/373 
-0.14 
(-0.34,0.06) 
-0.24 
(-0.60,0.12) 
-3.84,3.35 
-0.06 
(-0.28,0.16) 
42% 
(0%,83%) 
- 
6 Arnaout 2015 DBS (STN) DBS (GPi) Effect. Con 
Semantic verbal 
fluency 
3 -/373 
-0.05 
(-0.25,0.16) 
-0.05 
(-0.25,0.16) 
-1.38,1.29 
-0.01 
(-0.24,0.22) 
0% 
(0%,73%) 
* 
7 Liu 2014† DBS (STN) DBS (GPi) Effect. Con 
UPDRS II (on-
medication) 
3 -/450 
-0.04 
(-0.23,0.14) 
0.01 
(-0.32,0.33) 
-3.33,3.35 
-0.18 
(-0.40,0.05) 
52% 
(0%,85%) 
- 
8 Liu 2014† DBS (STN) DBS (GPi) Effect. Con 
UPDRS III (off-
medication) 
5 -/518 
0.09 
(-0.09,0.26) 
0.12 
(-0.23,0.46) 
-0.94,1.17 
-0.07 
(-0.30,0.16) 
60% 
(0%,83%)* 
- 
9 Liu 2014‡ DBS (STN) DBS (GPi) Effect. Con 
UPDRS III (on-
medication) 
5 -/518 
0.00 
(-0.17,0.17) 
0.00 
(-0.21,0.21) 
-0.47,0.48 
-0.07 
(0.29,0.16) 
17% 
(0%,70%) 
- 
* p<0.05 
** p<0.01 
*** p<0.001 
†there was overlap with the poster report of Arnaout 2015, but the journal report was retained, due to completeness. 
‡there was overlap with the poster report of Arnaout 2015, and the journal report of Sako 2014, but the journal report of Liu 2014, was retained, due to completeness and increased number of included 
studies. 
¥ significance results originating from the test for Q. 
Abbreviations: FE, fixed-effect model; RE, random-effects model; N, number of studies; SMD, standardized mean difference; CI, confidence interval; PrI, predictive interval; DBS, deep brain stimulation; 
Bin, binary; Effect, effectiveness; NA, not applicable; STN, subthalamic nucleus; GPi, globus pallidus internus; AE, adverse effects; BDI-II, Beck depression inventory-II; LED, levodopa equivalent dose; 
UPDRS, unified Parkinson's disease rating scale. 
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Effectiveness and adverse effects of deep brain stimulation: umbrella review of meta-analyses 
Appendices 
Appendix A Search strategies used for each database with the corresponding hits 
Database Search strategy Limits Hits Duplicates Unique 
MEDLINE searched via PubMed (1950 –31.03.2015) 
www.ncbi.nlm.nih.gov/sites/entrez/ 
"deep brain stimulation" Meta-analysis 28 0 28 
Scopus (1966 - 31.03.2015) searched from 
www.scopus.com 
"deep brain stimulation" AND ("systematic 
review" OR "meta-analysis") 
Meta-analysis 49 14 35 
CDSR & DARE searched via Cochrane Library on 
31.03.2015 from www.thecochranelibrary.com 
"deep brain stimulation" 
Cochrane & other 
Reviews 
23 14 9 
Abbreviation: CDSR = Cochrane Database of Systematic Reviews; DARE = Database of Abstracts of Reviews of Effects. 
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Appendix B List of full text papers assessed for eligibility 
Paper Status 
Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated 
with transcranial direct current stimulation. Int J Neuropsychopharmacol 2011;14:1133-45. 
Excluded; not related to DBS 
Ferreira JJ, Costa J, Coelho M, Sampaio C. The management of cervical dystonia. Expert Opin Pharmacother 2007;8:129-40. Excluded; not related to DBS 
Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 
2001 to 2004. Mov Disord 2005;20:523-39. 
Excluded; not related to DBS 
Slotema CW, Blom JD, Van Lutterveld R, Hoek HW, Sommer IEC. Review of the efficacy of transcranial magnetic stimulation for auditory verbal 
hallucinations. Biol Psychiatry 2014;76:101-10. 
Excluded; not related to DBS 
Berlim MT, Neufeld NH, Eynde F. Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory meta-
analysis of randomized and sham-controlled trials. J Psychiatr Res 2013;8:999-1006. 
Excluded; not related to DBS 
Adeyemo BO, Simis M, Duarte Macea D, Fregni F. Systematic review of parameters of stimulation, clinical trial design characteristics, and motor 
outcomes in non-invasive brain stimulation in stroke. Front Psychiatry 2012;1:88. 
Excluded; not related to DBS 
Puig-Junoy J, Puig Peiro R. [Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease]. Neurologia 
(Barcelona, Spain) 2009;24:220-9. 
Excluded; no quantitative 
synthesis 
Dannon PN, Lowengrub K, Gonopolski Y, Kotler M. Current and emerging somatic treatment strategies in psychotic major depression. Expert Rev Med 
Devices 2006;6:73-80. 
Excluded; no quantitative 
synthesis 
Fasano A, Bove F, Lang AE. The treatment of dystonic tremor: A systematic review. J Neurol Neurosurg Psychiatry 2014;85:759-69. 
Excluded; no quantitative 
synthesis 
Grill WM. Safety considerations for deep brain stimulation: Review and analysis. Expert Rev Med Devices 2005;2:409-20. 
Excluded; no quantitative 
synthesis 
Gahr M, Connemann BJ, Freudenmann RW, Schonfeldt-Lecuona C. Safety of electroconvulsive therapy in the presence of cranial metallic objects. J 
ECT 2014;30:62-8. 
Excluded; no quantitative 
synthesis 
Takeshita S, Kurisu K, Trop L, Arita K, Akimitsu T, Verhoeff NP. Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of 
previous facts and problems. Neurosurg Rev 2005;28:179-86. 
Excluded; no quantitative 
synthesis 
Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced 
Parkinson disease: a systematic review. Parkinsonism Relat Disord 2006;12:265-72. 
Excluded; no quantitative 
synthesis 
Vidailhet M, Jutras MF, Grabli D, Roze E. Deep brain stimulation for dystonia. J Neurol Neurosurg Psychiatry 2013;84:1029-42. 
Excluded; no quantitative 
synthesis 
Arumugham SS, Reddy JY. Augmentation strategies in obsessive-compulsive disorder. Expert Rev Neurother 2013;13:187-203. 
Excluded; no quantitative 
synthesis 
Fitzgerald PB. A review of developments in brain stimulation and the treatment of psychiatric disorders. Curr Psychiatry Rev 2006;2:199-205. 
Excluded; no quantitative 
synthesis 
Loo C, Katalinic N, Mitchell PB, Greenberg B. Physical treatments for bipolar disorder: A review of electroconvulsive therapy, stereotactic surgery and 
other brain stimulation techniques. J Affect Disord 2011;132:1-13. 
Excluded; no quantitative 
synthesis 
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Hamani C, Pilitsis J, Rughani AI, Rosenow JM, Patil PG, Slavin KS, Abosch A, Eskandar E, Mitchell LS, Kalkanis S. Deep brain stimulation for 
obsessive-compulsive disorder: systematic review and evidence-based guideline sponsored by the American Society for Stereotactic and Functional 
Neurosurgery and the Congress of Neurological Surgeons (CNS) and endorsed by the CNS and American Association of Neurological Surgeons. 
Neurosurgery 2014;75:327-33. 
Excluded; no quantitative 
synthesis 
Department of Health, Australian Government. Deep brain stimulation for the symptoms of Parkinson's disease. Database of Abstracts of Reviews of 
Effects 2001;1:49. 
Excluded; no quantitative 
synthesis 
Romito LM, Albanese A. Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. J Neurol 
2010;Suppl2:S298-304. 
Excluded; no quantitative 
synthesis 
Nicholson T, Milne R. Pallidotomy, thalamotomy and deep brain stimulation for severe Parkinson's disease. Database of Abstracts of Reviews of 
Effects 1999;1:63. 
Excluded; no quantitative 
synthesis 
Jiang JL, Lo SF, Tsai ST, Chen SY. A systematic review of the impact of subthalamic nucleus stimulation on the quality of life of patients with 
Parkinson's disease. Database of Abstracts of Reviews of Effects 2014;1:15-20. 
Excluded; no quantitative 
synthesis 
Perestelo-Pérez L, Rivero-Santana A, Pérez-Ramos J, Serrano-Pérez P, Panetta J, Hilarion P. Deep brain stimulation in Parkinson's disease: meta-
analysis of randomized controlled trials. J Neurol 2014΄;261:2051-2060. 
Excluded; no trial-specific data; 
requested from authors 
Couto MI, Monteiro A, Oliveira A, Lunet N, Massano J. Depression and anxiety following Deep brain stimulation in Parkinson's disease: Systematic 
review and meta-analysis. Acta Med Port 2014;27:372-82. 
Excluded; no trial-specific data; 
requested from authors 
Appleby BS, Duggan PS, Regenberg A, Rabins PV. Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: A meta-
analysis of ten years' experience. Mov Disord 2007;22:1722-8. 
Excluded; not standard synthesis; 
averaging among studies 
Bittar RG, Kar-Purkayastha I, Owen SL, Bear RE, Green A, Wang S, et al. Deep brain stimulation for pain relief: a meta-analysis. J Clin Neurosci 
2005;12:515-9. 
Excluded; not standard synthesis; 
averaging among studies 
Stephen JH, Halpern CH, Barrios CJ, Balmuri U, Pisapia JM, Wolf JA, et al. Deep brain stimulation compared with methadone maintenance for the 
treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction 2012;107:624-34. 
Excluded; not standard synthesis; 
averaging among studies 
Rughani AI, Lozano AM. Surgical treatment of myoclonus dystonia syndrome. Mov Disord 2013;3:282-7. 
Excluded; not standard synthesis; 
averaging among studies 
Andrade P, Carrillo-Ruiz JD, Jiménez F. A systematic review of the efficacy of globus pallidus stimulation in the treatment of Parkinson's disease. J Clin 
Neurosci 2009;16:877-81. 
Excluded; not standard synthesis; 
averaging among studies followed 
by test between means 
Woods SP, Rippeth JD, Conover E, Carey CL, Parsons TD, Troster AI. Statistical power of studies examining the cognitive effects of subthalamic 
nucleus deep brain stimulation in Parkinson's disease. Clin Neuropsychol 2006;20:27-38. 
Excluded; not standard synthesis; 
averaging the power of included 
studies (no effect estimates) 
Koy A, Hellmich M, Pauls KA, Marks W, Lin JP, Fricke O, et al. Effects of deep brain stimulation in dyskinetic cerebral palsy: a meta-analysis. Mov 
Disord 2013;28:647-54. 
Excluded; not standard synthesis; 
correlation of single group 
estimates 
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Weaver F, Follett K, Hur K, Ippolito D, Stern M. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 
2005;103:956-67. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate 
Parsons TD, Rogers SA, Braaten AJ, Woods SP, Tröster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: 
a meta-analysis. Lancet Neurol 2006;5:578-88. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate 
Berlim MT, McGirr A, Van den Eynde F, Fleck MP, Giacobbe P. Effectiveness and acceptability of deep brain stimulation (DBS) of the subgenual 
cingulate cortex for treatment-resistant depression: a systematic review and exploratory meta-analysis. J Affect Disord 2014;159:31-8. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate 
Hoflich A, Savli M, Comasco E, Moser U, Novak K, Kasper S, et al. Neuropsychiatric deep brain stimulation for translational neuroimaging. Neuroimage 
2013;79:30-41. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate 
Kimmelman J, Duckworth K, Ramsay T, Voss T, Ravina B, Emborg ME. Risk of surgical delivery to deep nuclei: a meta-analysis. Mov Disord 
2011;26:1415-21. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate 
Boucai L, Cerquetti D, Merello M. Functional surgery for Parkinson's disease treatment: A structured analysis of a decade of published literature. Br J 
Neurosurg 2004;18:213-22. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate 
Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, et al. Subthalamic nucleus deep brain stimulation: summary and meta-
analysis of outcomes. Mov Disord 2006;21 Suppl 14:S290-304. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate followed by meta-
regression 
Holloway KL, Baron MS, Brown R, Cifu DX, Carne W, Ramakrishnan V. Deep brain stimulation for dystonia: A meta-analysis. Neuromodulation 
2006;9:253-61. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate followed by meta-
regression 
St. George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. 
Neurology 2010;75:1292-9. 
Excluded; not standard synthesis; 
meta-analysis of a single group 
estimate followed by meta-
regression 
Andrews C, Aviles-Olmos I, Hariz M, Foltynie T. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual 
patient outcomes.J Neurol Neurosurg Psychiatry 2010;81:1383-9. 
Excluded; not standard synthesis; 
only meta-regression 
Smith DF. Exploratory meta-analysis on deep brain stimulation in treatment-resistant depression. Acta Neuropsychiatr 2014;26:382-4. 
Excluded; not standard synthesis; 
meta-analysis of a cohort studies 
with control data generated from 
field experts 
Sako W, Miyazaki Y, Izumi Y, Kaji R. Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic 
stimulation. J Neurol Neurosurg Psychiatry 2014;85:982-6. 
Included; published paper 
Chambers A, Bowen JM. Electrical stimulation for drug-resistant epilepsy: an evidence-based analysis. Ont Health Technol Assess Ser 2013;13:1-37. Included; published paper 
Liu Y, Li W, Tan C, Liu X, Wang X, Gui Y, et al. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat 
advanced Parkinson disease. J Neurosurg 2014;121:709-18. 
Included; published paper 
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Sprengers M, Vonck K, Carrette E, Marson AG, Boon P. Deep brain and cortical stimulation for epilepsy. Cochrane Database Syst Rev 
2014;6:CD008497. 
Included; published paper 
Kisely S, Hall K, Siskind D, Frater J, Olson S, Crompton D. Deep brain stimulation for obsessive-compulsive disorder: A systematic review and meta-
analysis. Psychol Med 2014;44:3533-42. 
Included; published paper 
Arnaout M, Negida A, El Ashal G, Fouda S, Ghanem E, El Ghonemy S. Meta-analysis comparing Subthalamic and Pallidal deep brain stimulation for 
patients with Parkinson's disease. Poster, ASIT conference 2015, Glasgow. 
Included; conference poster 
Negida A, Arnaout M, El Ashal G, Fouda S, Ghanem E, El Ghonemy S. Meta-analysis of mortality following Subthalamic and Pallidal deep brain 
stimulation for patients with Parkinson's disease. Poster, ASIT conference 2015, Glasgow. 
Included; conference poster 
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Appendix C Assessments of risk of bias and methodological quality for the included systematic reviews 
Assessment 
Chambers 
2013
32
 
Kisely 
2014
33
 
Liu 
2014
34
 
Sako 
2014
36
 
Sprengers 
2014
37
 
Arnaout 
2015
31
 
Negida 
2015
35
 
Risk of bias of primary studies 
Cochrane 
tool 
Cochrane 
tool 
Cochrane 
tool 
- 
Cochrane 
tool 
- - 
Quality of evidence (GRADE approach) Yes Yes - - Yes - - 
Methodological adequacy of systematic 
review (AMSTAR tool) 
7/11 5/11 7/11 2/11 11/11 NA NA 
Abbreviations: GRADE = Grading of Recommendations Assessment, Development and Evaluation; AMSTAR = A Measurement Tool to 
Assess Systematic Reviews; NA = not applicable. 
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Appendix D Assessment of the quality of the included systematic reviews with the AMSTAR tool 
No Item Arnaout
1
 Chambers
2
 Kisely
3
 Liu
4
 
Negida
5
 
Sako
6
 Sprengers
7
 
1 
Was an 'a priori' 
design provided? 
- No mention No mention No mention - No mention Yes (Cochrane Review) 
2 
Was there 
duplicate study 
selection and 
data extraction? 
- 
"Abstracts were 
reviewed by a single 
reviewer…" 
"Data extraction was 
conducted by two 
independent 
researchers (J.H. and 
J.F.). All discrepancies 
during all stages of 
study selection, data 
extraction and quality 
assessment were 
resolved by re-
checking source 
papers and further 
discussion among two 
other authors (S.K. 
and D.S.) to reach 
consensus." 
"Two reviewers (Y.L. and 
C.T.) independently 
applied the inclusion and 
exclusion criteria, 
selected the studies, and 
extracted data and 
outcomes" 
- 
"Two authors 
doublechecked the inclusion 
criteria of the identified 
studies. … Two authors 
independently extracted 
data and checked each 
other. Any discrepancies 
were resolved by 
discussion." 
"Four review authors (Mathieu 
Sprengers (MS),KristlVonck (KV), 
EvelienCarrette (EC) and Paul Boon 
(PB)) independently assessed the 
identified trials for inclusion." 
3 
Was a 
comprehensive 
literature search 
performed? 
- 
"..using Ovid 
MEDLINE, Ovid 
MEDLINE In-Process 
and Other Non-
Indexed Citations, 
Ovid EMBASE, the 
Wiley Cochrane 
Library, and the 
Centre for Reviews 
and Dissemination 
database…" 
"We conducted a 
comprehensive search 
using 
PubMed/Medline and 
EMBASE…" 
"MEDLINE/PubMed, 
EMBASE, Web of 
Knowledge, and the 
Cochrane Library were 
searched…" 
- 
"We searched the PubMed 
database for publication…" 
Three databases plus additional 
resources searched 
4 
Was the status of 
publication (i.e. 
grey literature) 
used as an 
inclusion 
criterion? 
- No mention 
Posters, conference 
abstracts, and other 
unpublished reports 
were excluded 
"Only published, English-
language manuscripts 
were ultimately included 
in analyses" 
- 
No mention of grey 
literature, while the inclusion 
criteria include the word 
"publications" 
"We contacted authors of relevant 
trials identified by our search, other 
researchers in the field, and 
manufacturers of the devices to 
identify unpublished or ongoing 
studies,…" 
5 
Was a list of 
studies (included 
and excluded) 
provided? 
- Not provided 
Excluded studies not 
listed 
Excluded studies not 
listed 
- Excluded studies not listed 
"References to studies excluded from 
this review" 
6 
Were the 
characteristics of 
the included 
studies provided? 
- Table 3 Table 1 
Table 1 (marginally 
extensive) 
- 
Characteristics missing from 
Table 1 
"Characteristics of included studies" 
7 
Was the scientific 
quality of the 
included studies 
assessed and 
documented? 
- Table A4 
"We assessed the 
quality of included 
studies using the 
following four criteria 
of the risk of bias 
assessment tool, 
developed by the 
Cochrane 
"the same 2 reviewers in 
strict accordance with the 
Introduction to the 
Cochrane Handbook for 
Systematic Reviews of 
Interventions..." 
- No assessment 
"The methodological quality of the 
studies was independently evaluated 
by two review authors (MS and KV) 
according to the guidelines in the 
Cochrane Handbook for Systematic 
Reviews of Interventions" 
8 
 
Collaboration…" 
8 
Was the scientific 
quality of the 
included studies 
used 
appropriately in 
formulating 
conclusions? 
- 
Conclusions 
accompanied with 
GRADE assessments 
No mention 
"Considering the 
limitations described 
above, caution should be 
taken in interpreting our 
findings" 
- No assessment 
No specific mention of quality of 
evidence in the Conclusions or 
Implications sections 
9 
Were the 
methods used to 
combine the 
findings of 
studies 
appropriate? 
- 
Heterogeneity 
reported only in the 
forest plots; although 
no mention is made in 
the text, the authors 
include a comment 
about inconsistency in 
the Summary of 
Findings table, 
indicating that it was 
assessed 
"We assessed 
heterogeneity using 
the I
2
 statistic,…" 
"Statistical analyses for 
continuous variables 
were performed, and 
heterogeneity was 
measured using I-square 
and chi-square tests." 
- 
"Random-effects models 
were employed for the 
meta-analysis because the 
underlying effect possibly 
differed across studies. The 
heterogeneity was 
assessed by a χ
2
 test and 
designated as Q" 
"Clinical heterogeneity was assessed 
by comparing the clinical and trial 
characteristics and a judgement was 
made as towhether significant clinical 
heterogeneity was present. Statistical 
inconsistency was assessed by visual 
inspection of the forest plots and by 
using the I² statistic and the Chi² test 
(Q test)." 
10 
Was the 
likelihood of 
publication bias 
assessed? 
- Assessed in table A1 
"We were unable to 
test for publication 
bias as there were 
insufficient studies for 
any of the outcomes" 
No mention - No mention 
"As no more than three trials could be 
identified for each individual target, 
we were not able to assess the risk of 
publication bias." 
11 
Was the conflict 
of interest 
included? 
- Assessed in table A1 
Conflicts of interest 
reported only for the 
review, not for the 
primary studies 
Conflicts of interest 
reported only for the 
review, not for the 
primary studies 
- 
Conflicts of interest reported 
only for the review, not for 
the primary studies 
Potential conflicts noted both for the 
primary studies and the review 
 
Sum NA 7/11 5/11 7/11 NA 2/11 10/11 
Abbreviation: NA = not applicable. 
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Appendix E Rating (Phase 2 and Phase 3) for each included systematic review according to the ROBIS 
tool 
      
REVIEW: CHAMBERS 2013 (2) 
Phase 2: Identifying concerns 
with the review process      
DOMAIN 1: STUDY ELIGIBILITY 
CRITERIA 
          
Describe the study eligibility 
criteria, any restrictions on 
eligibility and whether there was 
evidence that objectives and 
eligibility criteria were pre-
specified: 
Yes Probably Yes Probably No No No Information 
1.1 Did the review adhere to pre-
defined objectives and eligibility 
criteria? 
      
No mention of 
protocol or pre-
defined criteria  
  
1.2 Were the eligibility criteria 
appropriate for the review 
question? 
      
The primary 
research question 
entails information 
about the specific 
condition (drug-
resistant epilepsy) 
and the patients (not 
surgical candidates) 
that were missing 
from the criteria  
  
1.3 Were eligibility criteria 
unambiguous? 
      
The eligibility criteria 
were vague 
including the 
diagnosis modality, 
the treatments 
included and the 
technical details 
(stimulation 
magnitude, 
frequency, etc) 
  
1.4 Were all restrictions in 
eligibility criteria based on study 
characteristics appropriate (e.g. 
date, sample size, study quality, 
outcomes measured)? 
      
Search started from 
2007 on, as the 
relied on a previous 
HTA report that 
covered studies up 
to 2007. Certain 
studies however 
might have been 
missed.  
  
1.5 Were any restrictions in 
eligibility criteria based on sources 
of information appropriate (e.g. 
publication status or format, 
language, availability of data)? 
  
Probably ok, but no 
mention.  
      
  Low High Unclear     
Concerns regarding specification 
of study eligibility criteria 
  X       
Rationale for concern:   
No existing protocol, 
non-specific 
eligibility criteria 
about the diagnostic 
method and the 
differentiation 
between surgical 
and non-surgical 
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candidates. 
Eligibility criteria 
were not clear, while 
the literature 
searched started 
only from 2007. 
      
DOMAIN 2: IDENTIFICATION 
AND SELECTION OF STUDIES 
          
Describe methods of study 
identification and selection (e.g. 
number of reviewers involved): 
Yes Probably Yes Probably No No No Information 
2.1 Did the search include an 
appropriate range of 
databases/electronic sources for 
published and unpublished 
reports? 
 Authors searched 
MEDLINE, 
MEDLINE In-
Process and Other 
Non-Indexed 
Citations, EMBASE, 
the Wiley Cochrane 
Library (although not 
specified which 
database), and the 
CRD. 
        
2.2 Were methods additional to 
database searching used to 
identify relevant reports? 
 Reference lists 
were checked. 
        
2.3 Were the terms and structure 
of the search strategy likely to 
retrieve as many eligible studies 
as possible? 
 Full and appropriate 
search is provided in 
Appendix 1. 
        
2.4 Were restrictions based on 
date, publication format, or 
language appropriate? 
      
English studies were 
excluded, which 
might introduce bias. 
  
2.5 Were efforts made to minimise 
error in selection of studies? 
      
 One reviewer 
screened abstracts 
and fulltexts. 
  
  Low High Unclear     
Concerns regarding methods used 
to identify and/or select studies 
   X       
Rationale for concern:   
 Restriction to 
studies in English 
and no efforts made 
to minimize error in 
study selection 
      
      
DOMAIN 3: DATA COLLECTION 
AND STUDY APPRAISAL 
          
Describe methods of data 
collection, what data were 
extracted from studies or 
collected through other means, 
how risk of bias was assessed 
(e.g. number of reviewers 
involved) and the tool used to 
assess risk of bias: 
Yes Probably Yes Probably No No No Information 
3.1 Were efforts made to minimise 
error in data collection? 
    
 No mention of data 
collection at all, but 
it is improbable that 
duplicate collection 
and appraisal was 
done. 
    
3.2 Were sufficient study 
characteristics available for both 
review authors and readers to be 
      
 Patient 
characteristics are 
inadequate 
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able to interpret the results? (diagnosis of 
epilepsy and 
degree). Study 
characteristics were 
also inadequate 
(single or 
multicenter). 
3.3 Were all relevant study results 
collected for use in the synthesis? 
    
 No mention on what 
data were collected 
and no mention on 
handling of missing 
data or data 
transformation. 
    
3.4 Was risk of bias (or 
methodological quality) formally 
assessed using appropriate 
criteria? 
 The Cochrane tool 
was used. 
        
3.5 Were efforts made to minimise 
error in risk of bias assessment? 
    
 No mention of 
second reviewer 
performing or 
checking the risk of 
bias assessments. 
    
  Low High Unclear     
Concerns regarding methods used 
to collect data and appraise 
studies 
  X        
Rationale for concern:   
Probably only a 
limited number of 
data were extracted 
from each trial, while 
it is improbable that 
error was controlled 
during risk of bias 
assessment  
      
      
DOMAIN 4: SYNTHESIS AND 
FINDINGS 
          
Describe synthesis methods: Yes Probably Yes Probably No No No Information 
4.1 Did the synthesis include all 
studies that it should? 
    
The study of Clarke 
et al was not used in 
the meta-analysis, 
due to missing 
outcome.  
    
4.2 Were all pre-defined analyses 
reported or departures explained? 
       No protocol.   
4.3 Was the synthesis appropriate 
given the nature and similarity in 
the research questions, study 
designs and outcomes across 
included studies? 
      
 The author pooled 
studies with different 
interventions and 
with different 
experimental/control 
groups. 
  
4.4 Was between-study variation 
(heterogeneity) minimal or 
addressed in the synthesis? 
 Heterogeneity was 
assessed with I-
square and Q test 
and no big evidence 
for inconsistency 
was found. 
        
4.5 Were the findings robust, e.g. 
as demonstrated through funnel 
plot or sensitivity analyses? 
      
 No sensitivity or 
additional analyses 
conducted. 
  
4.6 Were biases in primary studies 
minimal or addressed in the 
synthesis? 
      
 Studies/outcomes 
with high risk of bias 
are included in the 
analyses, but no 
appropriate 
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measures have 
been taken to 
incorprorate this in 
the review’s results 
accordingly. 
  Low High Unclear     
Concerns regarding the synthesis 
and findings 
LOW/HIGH/UNCLEAR 
  X        
Rationale for concern:   
Missing data from 
Clarke et al., 
absence of protocol 
to compare 
departures from 
analysis plan, 
inappropriate meta-
analyses (apples 
and oranges), no 
additional analyses 
to check for 
robustness and high 
risk of bias studies 
included without 
appropriate 
measures in the 
review.  
      
      
Phase 3: Judging risk of bias 
     
Summarize the concerns 
identified during the Phase 2 
assessment: 
     
Domain Concern 
Rationale for 
concern    
1. Concerns regarding 
specification of study eligibility 
criteria 
High 
No existing protocol, 
non-specific 
eligibility criteria 
about the diagnostic 
method and the 
differentiation 
between surgical 
and non-surgical 
candidates. 
Eligibility criteria 
were not clear, while 
the literature 
searched started 
only from 2007. 
   
2. Concerns regarding methods 
used to identify and/or select 
studies 
High 
 Restriction to 
studies in English 
and no efforts made 
to minimize error in 
study selection 
   
3. Concerns regarding methods 
used to collect data and appraise 
studies 
High  
Probably only a 
limited number of 
data were extracted 
from each trial, while 
it is improbable that 
error was controlled 
during risk of bias 
assessment  
   
4. Concerns regarding the 
synthesis and findings 
High  
Missing data from 
Clarke et al., 
absence of protocol 
to compare 
departures from 
   
13 
 
analysis plan, 
inappropriate meta-
analyses (apples 
and oranges), no 
additional analyses 
to check for 
robustness and high 
risk of bias studies 
included without 
appropriate 
measures in the 
review.  
      
RISK OF BIAS IN THE REVIEW           
Describe whether conclusions 
were supported by the 
evidence: 
Yes Probably Yes Probably No No No Information 
A. Did the interpretation of findings 
address all of the concerns 
identified in Domains 1 to 4? 
      
Not all issues are 
addressed in the 
review.  
  
B. Was the relevance of identified 
studies to the review's research 
question appropriately 
considered? 
      
Only part of the 
research questions 
were answered from 
the included studies. 
Although, the 
effectiveness of 
DBS and VNS was 
the scope of the 
review, many 
studies included no 
untreated control 
and only compared 
low to high 
stimulation, which is 
no direct 
effectiveness 
measure. 
  
C. Did the reviewers avoid 
emphasizing results on the basis 
of their statistical significance? 
      
 No, the authors 
focused mainly on 
the statistical 
significance of the 
findings. 
  
  Low High Unclear     
Risk of bias in the review risk:   X        
Rationale for risk:   
Many residual 
issues regarding all 
methodological 
aspects of the 
review that were not 
taken into account in 
the review’s 
conclusions. 
Additionally, most 
studies compared 
only a relative 
effectiveness 
between low and 
high stimulation, but 
no absolute 
effectiveness 
compared to no 
treatment.  
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SR: KISELY 2014 (3) 
Phase 2: Identifying concerns 
with the review process      
DOMAIN 1: STUDY ELIGIBILITY 
CRITERIA 
          
Describe the study eligibility 
criteria, any restrictions on 
eligibility and whether there was 
evidence that objectives and 
eligibility criteria were pre-
specified: 
Yes Probably Yes Probably No No No Information 
1.1 Did the review adhere to pre-
defined objectives and eligibility 
criteria? 
      
No relevant 
information 
provided. 
  
1.2 Were the eligibility criteria 
appropriate for the review 
question? 
  
Eligibility criteria 
probably 
appropriate. The 
patient component is 
vague and not good 
defined, but this 
probably lies on the 
broad question of 
the review. 
      
1.3 Were eligibility criteria 
unambiguous? 
Eligibility criteria 
clearly-defined. 
Some ambiguitiy 
regarding the 
inclusion of various 
study designs, but 
the authors 
acknowledge it and 
take appropriate 
steps. 
        
1.4 Were all restrictions in 
eligibility criteria based on study 
characteristics appropriate (e.g. 
date, sample size, study quality, 
outcomes measured)? 
No restrictions 
imposed. 
        
1.5 Were any restrictions in 
eligibility criteria based on sources 
of information appropriate (e.g. 
publication status or format, 
language, availability of data)? 
No restrictions 
imposed. 
        
  Low High Unclear     
Concerns regarding specification 
of study eligibility criteria 
  X       
Rationale for concern:   
No evidence of a 
priori design for the 
review procedures 
and this is difficult to 
judge, due to 
missing pertinent 
information. 
      
X 
     
DOMAIN 2: IDENTIFICATION 
AND SELECTION OF STUDIES 
          
Describe methods of study 
identification and selection (e.g. 
number of reviewers involved): 
Yes Probably Yes Probably No No No Information 
2.1 Did the search include an 
appropriate range of 
databases/electronic sources for 
published and unpublished 
    
Only PubMed and 
Embase were 
searched. These 
two databases have 
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reports? large overlap, limited 
coverage and very 
little gray or non-
English literature. 
2.2 Were methods additional to 
database searching used to 
identify relevant reports? 
      No mention.   
2.3 Were the terms and structure 
of the search strategy likely to 
retrieve as many eligible studies 
as possible? 
        
The full search 
strategy was not 
reported and there 
were no details of 
the search terms; 
there was therefore 
no information on 
which to base the 
assessment for this 
question. 
2.4 Were restrictions based on 
date, publication format, or 
language appropriate? 
No restrictions 
mentioned. 
        
2.5 Were efforts made to minimise 
error in selection of studies? 
      
No mention of 
duplicate 
procedures—study 
selection was 
probably done from 
a single reviewer 
without error 
management. 
  
  Low High Unclear     
Concerns regarding methods used 
to identify and/or select studies 
  X       
Rationale for concern:   
Limited literature 
search, without 
additional methods 
to maximize 
identification of 
studies, incomplete 
reporting and high 
risk of error during 
the study selection. 
      
      
DOMAIN 3: DATA COLLECTION 
AND STUDY APPRAISAL 
          
Describe methods of data 
collection, what data were 
extracted from studies or 
collected through other means, 
how risk of bias was assessed 
(e.g. number of reviewers 
involved) and the tool used to 
assess risk of bias: 
Yes Probably Yes Probably No No No Information 
3.1 Were efforts made to minimise 
error in data collection? 
Procedures 
performed 
independently by 
two authors. 
        
3.2 Were sufficient study 
characteristics available for both 
review authors and readers to be 
able to interpret the results? 
Data collected and 
reported in Table 1 
seem adequate 
(study design, 
patients allocated-
finished, DBS 
information, and 
outcomes reported). 
        
3.3 Were all relevant study results 
collected for use in the synthesis? 
  
Some information 
about the patient 
samples are missing 
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from some studies, 
probably due to 
incomplete reporting 
from the studies. 
3.4 Was risk of bias (or 
methodological quality) formally 
assessed using appropriate 
criteria? 
The Cochrane tool 
was used. 
        
3.5 Were efforts made to minimise 
error in risk of bias assessment? 
Procedures 
performed 
independently by 
two authors. 
        
  Low High Unclear     
Concerns regarding methods used 
to collect data and appraise 
studies 
 X         
Rationale for concern: 
Data collection and 
risk of bias 
assessment done 
under management 
of probable errors. 
Data collected are 
probably adequate, 
while an appropriate 
risk-of-bias tool was 
used (Cochrane 
tool).  
        
      
DOMAIN 4: SYNTHESIS AND 
FINDINGS 
          
Describe synthesis methods: Yes Probably Yes Probably No No No Information 
4.1 Did the synthesis include all 
studies that it should? 
All studies are 
included 
(flowdiagrama vs 
forest plot). 
        
4.2 Were all pre-defined analyses 
reported or departures explained? 
      No protocol existed.   
4.3 Was the synthesis appropriate 
given the nature and similarity in 
the research questions, study 
designs and outcomes across 
included studies? 
Appropriate 
comparisons with 
similar PICOS. Both 
changes in end 
measurements and 
Pre-Post increments 
are pooled. This has 
been shown to be 
appropriate through 
empirical studies. 
The authors, 
assessed also these 
two measures 
independently. 
        
4.4 Was between-study variation 
(heterogeneity) minimal or 
addressed in the synthesis? 
Tau-squared 
moderate. I-square 
and Q don’t indicate 
excessive 
inconsistency. 
        
4.5 Were the findings robust, e.g. 
as demonstrated through funnel 
plot or sensitivity analyses? 
Sensitivity and 
subgroup analyses 
were planned and 
conducted, but were 
not always possible. 
        
4.6 Were biases in primary studies 
minimal or addressed in the 
synthesis? 
    
The authors 
acknowledge that 
outcomes were 
missing from 80% of 
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the included studies. 
  Low High Unclear     
Concerns regarding the synthesis 
and findings 
LOW/HIGH/UNCLEAR 
  X       
Rationale for concern:   
Missing outcomes 
from 4/5 of the 
included studies and 
no existing protocol 
to judge any 
possible departures 
from analysis plan. 
      
      
Phase 3: Judging risk of bias 
     
Summarize the concerns 
identified during the Phase 2 
assessment: 
     
Domain Concern 
Rationale for 
concern    
1. Concerns regarding 
specification of study eligibility 
criteria 
High 
No evidence of a 
priori design for the 
review procedures 
and this is difficult to 
judge, due to 
missing pertinent 
information. 
   
2. Concerns regarding methods 
used to identify and/or select 
studies 
High 
Limited literature 
search, without 
additional methods 
to maximize 
identification of 
studies, incomplete 
reporting and high 
risk of error during 
the study selection. 
   
3. Concerns regarding methods 
used to collect data and appraise 
studies 
Low  
Data collection and 
risk of bias 
assessment done 
under management 
of probable errors. 
Data collected are 
probably adequate, 
while an appropriate 
risk-of-bias tool was 
used (Cochrane 
tool).  
   
4. Concerns regarding the 
synthesis and findings 
High  
Missing outcomes 
from 4/5 of the 
included studies and 
no existing protocol 
to judge any 
possible departures 
from analysis plan. 
   
      
RISK OF BIAS IN THE REVIEW           
Describe whether conclusions 
were supported by the 
evidence: 
Yes Probably Yes Probably No No No Information 
A. Did the interpretation of findings 
address all of the concerns 
identified in Domains 1 to 4? 
      
Not all concerns 
addressed. 
  
B. Was the relevance of identified 
studies to the review's research 
 Relevant studies for 
the review’s 
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question appropriately 
considered? 
question 
C. Did the reviewers avoid 
emphasizing results on the basis 
of their statistical significance? 
Authors clearly 
acknowledge that 
significance testing 
might have been 
confounded by 
limited samples.  
        
  Low High Unclear     
Risk of bias in the review risk:   X       
Rationale for risk:   
Absence of protocol 
to judge a priori 
design and no 
mention of pre-
defined criteria. 
Limited literature 
search and risk of 
error during study 
selection. Missing 
outcomes in 4/5 
included studies and 
authors’ judgement 
about possible risk 
of publication bias. 
      
      
      
SR: LIU 2014 (4) 
Phase 2: Identifying concerns 
with the review process      
DOMAIN 1: STUDY ELIGIBILITY 
CRITERIA 
          
Describe the study eligibility 
criteria, any restrictions on 
eligibility and whether there was 
evidence that objectives and 
eligibility criteria were pre-
specified: 
Yes Probably Yes Probably No No No Information 
1.1 Did the review adhere to pre-
defined objectives and eligibility 
criteria? 
      
No protocol 
provided. 
  
1.2 Were the eligibility criteria 
appropriate for the review 
question? 
Yes, the eligibility 
criteria were 
relatively clear and, 
in any way, more 
specific than the 
research question. 
All PICOS 
components are 
covered. 
        
1.3 Were eligibility criteria 
unambiguous? 
Eligibility criteria 
clear enough. 
        
1.4 Were all restrictions in 
eligibility criteria based on study 
characteristics appropriate (e.g. 
date, sample size, study quality, 
outcomes measured)? 
No pertinent 
eligibility criteria. 
        
1.5 Were any restrictions in 
eligibility criteria based on sources 
of information appropriate (e.g. 
publication status or format, 
language, availability of data)? 
      
Only published and 
English language 
studies were 
included. 
  
  Low High Unclear     
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Concerns regarding specification 
of study eligibility criteria 
  X       
Rationale for concern:   
The systematic 
review was not 
registered, while 
only English and 
published studies 
were included, 
which can introduce 
bias. 
      
      
DOMAIN 2: IDENTIFICATION 
AND SELECTION OF STUDIES 
          
Describe methods of study 
identification and selection (e.g. 
number of reviewers involved): 
Yes Probably Yes Probably No No No Information 
2.1 Did the search include an 
appropriate range of 
databases/electronic sources for 
published and unpublished 
reports? 
Yes; MEDLINE, 
Embase, Web of 
Knowledge and 
Cochrane Library 
(not specified which 
sub-library) were 
searched. 
        
2.2 Were methods additional to 
database searching used to 
identify relevant reports? 
Reference lists were 
checked. 
        
2.3 Were the terms and structure 
of the search strategy likely to 
retrieve as many eligible studies 
as possible? 
  
The complete 
search strategy is 
not provided; just 
keywords that were 
used and no obvious 
reason to assume 
inappropriateness 
exists. 
      
2.4 Were restrictions based on 
date, publication format, or 
language appropriate? 
      
Only published and 
English language 
studies were 
included. 
  
2.5 Were efforts made to minimise 
error in selection of studies? 
Duplicate study 
selection was 
performed. 
        
  Low High Unclear     
Concerns regarding methods used 
to identify and/or select studies 
  X       
Rationale for concern:   
Only published and 
English language 
studies were 
included. 
      
      
DOMAIN 3: DATA COLLECTION 
AND STUDY APPRAISAL 
          
Describe methods of data 
collection, what data were 
extracted from studies or 
collected through other means, 
how risk of bias was assessed 
(e.g. number of reviewers 
involved) and the tool used to 
assess risk of bias: 
Yes Probably Yes Probably No No No Information 
3.1 Were efforts made to minimise 
error in data collection? 
Duplicate data 
collection was 
performed. 
        
3.2 Were sufficient study 
characteristics available for both 
    
Some data missing 
from the included 
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review authors and readers to be 
able to interpret the results? 
studies. 
3.3 Were all relevant study results 
collected for use in the synthesis? 
  
Some data were 
missing: study 
design (single- or 
multicenter), study 
setting, severity of 
disease, technical 
details of the 
intervention. 
      
3.4 Was risk of bias (or 
methodological quality) formally 
assessed using appropriate 
criteria? 
Yes (Cochrane tool 
was used. 
        
3.5 Were efforts made to minimise 
error in risk of bias assessment? 
Duplicate risk of bias 
assessment was 
performed. 
        
  Low High Unclear     
Concerns regarding methods used 
to collect data and appraise 
studies 
  X       
Rationale for concern:   
Some data missing 
from the included 
studies. 
      
      
DOMAIN 4: SYNTHESIS AND 
FINDINGS 
          
Describe synthesis methods: Yes Probably Yes Probably No No No Information 
4.1 Did the synthesis include all 
studies that it should? 
      
Incomplete reporting 
from the included 
studies meant that 
many studies were 
omitted from the 
analyses. Half of the 
trials on adverse 
effects reported 
incomplete data. 
  
4.2 Were all pre-defined analyses 
reported or departures explained? 
      
No protocol 
available. The post 
hoc model choice 
indicates that no a 
priori analysis plan 
was made. 
  
4.3 Was the synthesis appropriate 
given the nature and similarity in 
the research questions, study 
designs and outcomes across 
included studies? 
Analyses were 
appropriate. 
        
4.4 Was between-study variation 
(heterogeneity) minimal or 
addressed in the synthesis? 
Moderate 
heterogeneity was 
identified and was 
assessed with 
sensitivity analyses. 
        
4.5 Were the findings robust, e.g. 
as demonstrated through funnel 
plot or sensitivity analyses? 
All sensitivity 
analyses that were 
performed (by 
omission of a single 
study) indicated 
robustness. 
        
4.6 Were biases in primary studies 
minimal or addressed in the 
synthesis? 
    
A trial had high risk 
of bias for one 
domain, but this was 
not incorporated in 
synthesis. Otherwise 
the included trials 
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had unclear risk of 
bias for many 
domains. 
  Low High Unclear     
Concerns regarding the synthesis 
and findings 
LOW/HIGH/UNCLEAR 
  X       
Rationale for concern:   
Amon the 11 
excluded studies 
were also studies 
with non-extractable 
results. Half of the 
trials on adverse 
effects reported 
incomplete data. No 
protocol available. 
The post hoc model 
choice indicates that 
no a priori analysis 
plan was made. 
      
      
Phase 3: Judging risk of bias 
     
Summarize the concerns 
identified during the Phase 2 
assessment: 
     
Domain Concern 
Rationale for 
concern    
1. Concerns regarding 
specification of study eligibility 
criteria 
High 
The systematic 
review was not 
registered, while 
only English and 
published studies 
were included, 
which can introduce 
bias. 
   
2. Concerns regarding methods 
used to identify and/or select 
studies 
High 
Only published and 
English language 
studies were 
included. 
   
3. Concerns regarding methods 
used to collect data and appraise 
studies 
High  
Some data missing 
from the included 
studies. 
   
4. Concerns regarding the 
synthesis and findings 
High  
Amon the 11 
excluded studies 
were also studies 
with non-extractable 
results. Half of the 
trials on adverse 
effects reported 
incomplete data. No 
protocol available. 
The post hoc model 
choice indicates that 
no a priori analysis 
plan was made. 
   
      
RISK OF BIAS IN THE REVIEW           
Describe whether conclusions 
were supported by the 
evidence: 
Yes Probably Yes Probably No No No Information 
A. Did the interpretation of findings 
address all of the concerns 
identified in Domains 1 to 4? 
    
English language 
and missing data 
were addressed by 
the authors of the 
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review. Absence of 
gray literature and 
missing a priori 
design for the review 
and analysis plan 
are not reported.  
B. Was the relevance of identified 
studies to the review's research 
question appropriately 
considered? 
Judged as 
appropriate. 
        
C. Did the reviewers avoid 
emphasizing results on the basis 
of their statistical significance? 
      
Interpretation is 
based mainly on the 
statistical 
signifcance of the 
overall pooled 
estimate. For many 
forest plots, the 
included trials 
provide 
contradictory results. 
  
  Low High Unclear     
Risk of bias in the review risk:   X       
Rationale for risk:   
Absence of gray 
literature and 
missing a priori 
design for the review 
and analysis plan 
are not reported. 
Interpretation is 
based mainly on the 
statistical 
signifcance of the 
overall pooled 
estimate. For many 
forest plots, the 
included trials 
provide 
contradictory 
results.  
      
      
      
ROBIS TOOL – SR: SAKO 2014 (6) 
Phase 2: Identifying concerns 
with the review process      
DOMAIN 1: STUDY ELIGIBILITY 
CRITERIA 
          
Describe the study eligibility 
criteria, any restrictions on 
eligibility and whether there was 
evidence that objectives and 
eligibility criteria were pre-
specified: 
Yes Probably Yes Probably No No No Information 
1.1 Did the review adhere to pre-
defined objectives and eligibility 
criteria? 
      
No protocol 
provided. 
  
1.2 Were the eligibility criteria 
appropriate for the review 
question? 
  
No clear research 
question. The 
eligibility criteria 
however were clear 
enough and would 
match the general 
framework of the 
question. 
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1.3 Were eligibility criteria 
unambiguous? 
The eligibility criteria 
were clear. 
        
1.4 Were all restrictions in 
eligibility criteria based on study 
characteristics appropriate (e.g. 
date, sample size, study quality, 
outcomes measured)? 
      
Search starting date 
was set at 1995 
without justification. 
Setting a minimum 
of 10 patients seems 
logical. 
  
1.5 Were any restrictions in 
eligibility criteria based on sources 
of information appropriate (e.g. 
publication status or format, 
language, availability of data)? 
      
It is not explicitely 
stated that only 
published papers 
were included, but 
MEDLINE that was 
searched, indexes 
manily published 
reports. The authors 
also included only 
English papers. 
  
  Low High Unclear     
Concerns regarding specification 
of study eligibility criteria 
  X       
Rationale for concern:   
No protocol 
provided, search 
limited to studies 
published after 1995 
and only in English 
language. 
      
      
DOMAIN 2: IDENTIFICATION 
AND SELECTION OF STUDIES 
          
Describe methods of study 
identification and selection (e.g. 
number of reviewers involved): 
Yes Probably Yes Probably No No No Information 
2.1 Did the search include an 
appropriate range of 
databases/electronic sources for 
published and unpublished 
reports? 
      
Only MEDLINE was 
searched. 
  
2.2 Were methods additional to 
database searching used to 
identify relevant reports? 
      
No additional search 
methods. Four 
additional papers 
were found from 
existing review 
articles, but this was 
not judged as an 
appropriate adjunct 
to database search. 
  
2.3 Were the terms and structure 
of the search strategy likely to 
retrieve as many eligible studies 
as possible? 
  
No complete search 
strategy reported, 
but the provided 
terms seem 
appropriate. 
      
2.4 Were restrictions based on 
date, publication format, or 
language appropriate? 
      
Inappropriate 
restrictions 
regarding date, 
language, and 
(possibly) format. 
  
2.5 Were efforts made to minimise 
error in selection of studies? 
Two reviewers 
selected / checked 
eligible studies. 
        
  Low High Unclear     
Concerns regarding methods used 
to identify and/or select studies 
  X       
Rationale for concern:   Limited database       
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search and no 
additional search 
methods, together 
with inappropriate 
restrictions, might 
have resulted in 
missing a potentially 
eligible trial. 
      
DOMAIN 3: DATA COLLECTION 
AND STUDY APPRAISAL 
          
Describe methods of data 
collection, what data were 
extracted from studies or 
collected through other means, 
how risk of bias was assessed 
(e.g. number of reviewers 
involved) and the tool used to 
assess risk of bias: 
Yes Probably Yes Probably No No No Information 
3.1 Were efforts made to minimise 
error in data collection? 
Duplicate procedure 
by two authors. 
        
3.2 Were sufficient study 
characteristics available for both 
review authors and readers to be 
able to interpret the results? 
      
Missing information 
about the design 
and setting of 
included trials. No 
data about diagnosis 
and severity of the 
disease extracted. 
  
3.3 Were all relevant study results 
collected for use in the synthesis? 
      
Missing data from 
trials in Table 1. 
  
3.4 Was risk of bias (or 
methodological quality) formally 
assessed using appropriate 
criteria? 
      
Not risk of bias 
assessment. 
  
3.5 Were efforts made to minimise 
error in risk of bias assessment? 
      
Not risk of bias 
assessment. 
  
  Low High Unclear     
Concerns regarding methods used 
to collect data and appraise 
studies 
  X       
Rationale for concern:   
Limited data 
collected from the 
included trials, 
incomplete data 
reporting from the 
included trials and 
formal assessment 
of risk of bias. 
      
      
DOMAIN 4: SYNTHESIS AND 
FINDINGS 
          
Describe synthesis methods: Yes Probably Yes Probably No No No Information 
4.1 Did the synthesis include all 
studies that it should? 
All trials included in 
the meta-analysis. 
        
4.2 Were all pre-defined analyses 
reported or departures explained? 
      
No protocol 
provided. 
  
4.3 Was the synthesis appropriate 
given the nature and similarity in 
the research questions, study 
designs and outcomes across 
included studies? 
Judged as 
appropriate. 
        
4.4 Was between-study variation 
(heterogeneity) minimal or 
addressed in the synthesis? 
  
Moderate 
inconsistency 
detected, while 
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direction of effects is 
unanimous. 
4.5 Were the findings robust, e.g. 
as demonstrated through funnel 
plot or sensitivity analyses? 
      
No additional 
analyses conducted. 
  
4.6 Were biases in primary studies 
minimal or addressed in the 
synthesis? 
      
Biases were not 
addressed in 
general. 
  
  Low High Unclear     
Concerns regarding the synthesis 
and findings 
LOW/HIGH/UNCLEAR 
  X       
Rationale for concern:   
Absence of a pre-
defined analysis 
plan, while 
additional analyses 
and sensitivity 
analyses were not 
conducted. 
      
      
Phase 3: Judging risk of bias 
     
Summarize the concerns 
identified during the Phase 2 
assessment: 
     
Domain Concern 
Rationale for 
concern    
1. Concerns regarding 
specification of study eligibility 
criteria 
High 
No protocol 
provided, search 
limited to studies 
published after 1995 
and only in English 
language. 
   
2. Concerns regarding methods 
used to identify and/or select 
studies 
High 
Limited database 
search and no 
additional search 
methods, together 
with inappropriate 
restrictions, might 
have resulted in 
missing a potentially 
eligible trial. 
   
3. Concerns regarding methods 
used to collect data and appraise 
studies 
High  
Limited data 
collected from the 
included trials, 
incomplete data 
reporting from the 
included trials and 
formal assessment 
of risk of bias. 
   
4. Concerns regarding the 
synthesis and findings 
High  
Absence of a pre-
defined analysis 
plan, while 
additional analyses 
and sensitivity 
analyses were not 
conducted. 
   
      
RISK OF BIAS IN THE REVIEW           
Describe whether conclusions 
were supported by the 
evidence: 
Yes Probably Yes Probably No No No Information 
A. Did the interpretation of findings 
address all of the concerns 
      
No; most of the 
concerns remained 
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identified in Domains 1 to 4? unadressed by the 
authors. 
B. Was the relevance of identified 
studies to the review's research 
question appropriately 
considered? 
 Probably yes, as 
the research 
question was very 
broad. 
        
C. Did the reviewers avoid 
emphasizing results on the basis 
of their statistical significance? 
      
No; statistical 
significance was the 
main factor of focus. 
  
  Low High Unclear     
Risk of bias in the review risk:   X       
Rationale for risk:   
Residual concerns 
that were identified 
in Phase 2 and 
remained 
unaddressed. 
      
      
      
REVIEW: SPRENGERS 2014 (7) 
Phase 2: Identifying concerns 
with the review process      
DOMAIN 1: STUDY ELIGIBILITY 
CRITERIA 
          
Describe the study eligibility 
criteria, any restrictions on 
eligibility and whether there was 
evidence that objectives and 
eligibility criteria were pre-
specified: 
Yes Probably Yes Probably No No No Information 
1.1 Did the review adhere to pre-
defined objectives and eligibility 
criteria? 
Yes, as it was a 
Cochrane Review. 
        
1.2 Were the eligibility criteria 
appropriate for the review 
question? 
Yes, criteria properly 
fit the question. 
        
1.3 Were eligibility criteria 
unambiguous? 
Eligibility criteria 
were clear and 
specific. 
        
1.4 Were all restrictions in 
eligibility criteria based on study 
characteristics appropriate (e.g. 
date, sample size, study quality, 
outcomes measured)? 
No restrictions 
imposed. 
        
1.5 Were any restrictions in 
eligibility criteria based on sources 
of information appropriate (e.g. 
publication status or format, 
language, availability of data)? 
No restrictions 
imposed. 
        
  Low High Unclear     
Concerns regarding specification 
of study eligibility criteria 
X          
Rationale for concern: No concern          
      
DOMAIN 2: IDENTIFICATION 
AND SELECTION OF STUDIES 
          
Describe methods of study 
identification and selection (e.g. 
number of reviewers involved): 
Yes Probably Yes Probably No No No Information 
2.1 Did the search include an 
appropriate range of 
databases/electronic sources for 
MEDLINE, 
Cochrane special 
register from the 
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published and unpublished 
reports? 
Epilepsy group and 
CENTRAL. 
2.2 Were methods additional to 
database searching used to 
identify relevant reports? 
Reference lists, 
relevant and other 
authors’ contact, 
and manufacturers 
were investigated. 
        
2.3 Were the terms and structure 
of the search strategy likely to 
retrieve as many eligible studies 
as possible? 
Judged as 
appropriate. 
        
2.4 Were restrictions based on 
date, publication format, or 
language appropriate? 
None imposed.         
2.5 Were efforts made to minimise 
error in selection of studies? 
Selection by four 
authors 
independently. 
        
  Low High Unclear     
Concerns regarding methods used 
to identify and/or select studies 
X          
Rationale for concern:  No concern.         
      
DOMAIN 3: DATA COLLECTION 
AND STUDY APPRAISAL 
          
Describe methods of data 
collection, what data were 
extracted from studies or 
collected through other means, 
how risk of bias was assessed 
(e.g. number of reviewers 
involved) and the tool used to 
assess risk of bias: 
Yes Probably Yes Probably No No No Information 
3.1 Were efforts made to minimise 
error in data collection? 
Extraction from two 
authors 
independently. 
        
3.2 Were sufficient study 
characteristics available for both 
review authors and readers to be 
able to interpret the results? 
Adequate data 
extracted. 
        
3.3 Were all relevant study results 
collected for use in the synthesis? 
Adequate data were 
collected. In case of 
missing data, 
authors were 
contacted and/or the 
missing data were 
calculated. 
        
3.4 Was risk of bias (or 
methodological quality) formally 
assessed using appropriate 
criteria? 
With the Cochrane 
risk of bias tool. 
        
3.5 Were efforts made to minimise 
error in risk of bias assessment? 
Procedure 
conducted in 
duplicate. 
        
  Low High Unclear     
Concerns regarding methods used 
to collect data and appraise 
studies 
X          
Rationale for concern: No concern.          
      
DOMAIN 4: SYNTHESIS AND 
FINDINGS 
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Describe synthesis methods: Yes Probably Yes Probably No No No Information 
4.1 Did the synthesis include all 
studies that it should? 
Apparently yes.         
4.2 Were all pre-defined analyses 
reported or departures explained? 
All departures 
explained and 
justified. 
        
4.3 Was the synthesis appropriate 
given the nature and similarity in 
the research questions, study 
designs and outcomes across 
included studies? 
  
Synthesis 
appropriate in 
general terms, 
although model 
choice was based 
on post hoc 
availability of studies 
and post hoc 
inspection of 
statistical 
heterogeneity, which 
is not a robust 
justification. Clinical 
and statistical 
reasoning should 
be, at least in part, 
provided a priori. 
      
4.4 Was between-study variation 
(heterogeneity) minimal or 
addressed in the synthesis? 
Both clinical and 
statistical 
heterogeneity were 
assessed (the latter 
with I-square and 
Q). 
        
4.5 Were the findings robust, e.g. 
as demonstrated through funnel 
plot or sensitivity analyses? 
Subgroup analyses 
were planned and 
performed. 
Sensitivity analyses 
were planned, but 
could not be 
successfully 
conducted. 
        
4.6 Were biases in primary studies 
minimal or addressed in the 
synthesis? 
Fully incorporated 
both with the 
GRADE approacha 
and by consistent 
mentioning in the 
limitations and 
conclusions of the 
review. 
        
  Low High Unclear     
Concerns regarding the synthesis 
and findings 
LOW/HIGH/UNCLEAR 
X          
Rationale for concern: 
No (or only minor) 
concerns.  
        
      
Phase 3: Judging risk of bias 
     
Summarize the concerns 
identified during the Phase 2 
assessment: 
     
Domain Concern 
Rationale for 
concern    
1. Concerns regarding 
specification of study eligibility 
criteria 
Low No concerns 
   
2. Concerns regarding methods 
used to identify and/or select 
studies 
Low No concerns 
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3. Concerns regarding methods 
used to collect data and appraise 
studies 
Low  No concerns 
   
4. Concerns regarding the 
synthesis and findings 
Low  
No (or only minor) 
concerns    
      
RISK OF BIAS IN THE REVIEW           
Describe whether conclusions 
were supported by the 
evidence: 
Yes Probably Yes Probably No No No Information 
A. Did the interpretation of findings 
address all of the concerns 
identified in Domains 1 to 4? 
 Fully incorporated.         
B. Was the relevance of identified 
studies to the review's research 
question appropriately 
considered? 
 Direct relevance.         
C. Did the reviewers avoid 
emphasizing results on the basis 
of their statistical significance? 
 Interpretation 
together with 
associated 
uncertainty and 
possible 
confounders. 
        
  Low High Unclear     
Risk of bias in the review risk:  X         
Rationale for risk: No concerns          
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Appendix F Included studies’ matrix from meta-analyses with overlap 
Nature Effectiveness Adverse effects 
Outcom
e 
UPDRS II UPDRS III_off UPDRS III_on 
LE
D 
sema
ntic 
phon
etic 
≥50% 
seizure 
reduction 
BDI-II Depression Mortality 
Trial 1 2 7 8 10 11 2 5 7 8 9 
1
0 
1
1 
2 5 7 8 9 
1
0 
1
1 
2 7 3 4 7 3 4 7 6 3 5 7 9 
1
0 
2 5 7 9 
1
0 
2 4 8 
1
1 
Review 
                            
      
         Chamber
s 2013 
(2)                                                         
x 
                            
Liu 2014 
(4) 
  x x   x   x x x 
 
x x  x x x   x x   x x               x x x x x 
     
        
Sako 
2014 (6) 
            x x x 
  
x   x x x     x                                 x x   x         
Arnaout 
2015 (1) 
x x   x x x x x   x 
 
x 
 
x 
x
  
x x   x x x x     x x x x x x                               
Negida 
2015 (5) 
                                                                              x x x x 
 
Trial 
number 
Reference 
1 
Krause M, Fogel W, Heck A, et al. Deep brain stimulation for the treatment of Parkinson’s disease: subthalamic nucleus versus globus pallidus 
internus. J Neurol Neurosurg Psychiatry 2001;70:464-70. 
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pallidus as compared to the subthalamic nucleus. J Neurol 2009;256:1321-9. 
6 
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2010;51:899-908. 
7 
Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-
91. 
8 
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Disord 2010;25:578-86. 
9 
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Odekerken VJJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced 
Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 2013;12:37-44. 
11 
Weaver FM, Follett KA, Stern M, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 
2012;79:55-65. 
Abbreviations: UPDRS = unified Parkinson's disease rating scale; LED = levodopa equivalent dose; BDI-II = Beck depression 
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Appendix G Results from meta-analyses with overlap  
Outcome Meta-analysis N Cases/sample FE RE 95% PrI Largest trial I
2
 (95% CI) Egger 
UPDRS II Liu
4
 (included) 3 NA/450 -0·04 (-0·23,0·14) 0·01 (-0·32,0·33) -3·33,3·35 -0·18 (-0·40,0·05) 52% (0%,85%) - 
 Arnaout
1
 (omitted) 5 NA/373 -0·10 (-0·31,0·10) -0·10 (-0·31,0·10) -0·44,0·23 0·02 (-0·29,0·33) 0% (0%,64%) - 
 
 
  
   
 
  
UPDRS III (on-medication) Liu
4
 (included) 5 NA/518 0·09 (-0·09,0·26) 0·12 (-0·23,0·46) -0·94,1·17 -0·07 (-0·30,0·16) 60% (0%,83%)* - 
 Arnaout
1
 (excluded) 6 NA/426 0·04 (-0·15,0·23) 0·03 (-0·21,0·26) -0·49,0·55 0·32 (0·01,0·64) 24% (0%,70%) - 
 
 
  
   
 
  
UPDRS III (off-medication) Liu
4
 (included) 5 NA/518 0·00 (-0·17,0·17) 0·00 (-0·21,0·21) -0·47,0·48 -0·07 (0·29,0·16) 17% (0%,70%) - 
 Arnaout
1
 (omitted) 6 NA/426 -0·11 (-0·30,0·09) -0·12 (-0·44,0·20) -1·04,0·79 0·24 (-0·07,0·55) 56% (0%,80%)* * 
 Sako
6
 (omitted) 4 - 0·12 (-0·07,0·30) 0·19 (-0·20,0·58) -1·42,1·80 -0·09 (-0·33,0·15) 68% (0%,87%) - 
Abbreviations: FE = fixed-effect model; RE = random-effects model; PrI = predictive interval; CI = confidence interval; UPDRS = unified Parkinson's disease rating scale; NA = not 
applicable. 
*significant at the 10% level. 
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Appendix H Results of the sensitivity analysis according to basic study design 
.
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Appendix I Results from meta-analyses with overlap 
Meta-
analysis 
P<0·001 
Adequate 
sample 
I
2
<75% 
95% predictive interval 
excludes null 
No Egger 
P<0·10 
Meeting all 
criteria 
1 No No Yes No Yes No 
2 No No Yes No Yes No 
3 No No Yes No Yes No 
4 No No Yes No Yes No 
5 No No Yes No Yes No 
6 No No Yes No Yes No 
7 No No Yes No Yes No 
8 Yes No Yes Yes Yes No 
9 No No Yes No Yes No 
10 No No Yes No Yes No 
11 No No Yes No Yes No 
12 No No Yes No No No 
13 No No Yes No Yes No 
14 No No Yes No Yes No 
15 No No Yes No Yes No 
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